Lenire Sponsors Military Veterans Hearoes Tour
Lenire is sponsoring the 10th Annual Hearoes Tour to expand access to hearing and tinnitus care for U.S. veterans through free nationwide screenings and support.
Tag: Lenire
All
Latest
All
Latest
Case Study: Using Lenire on Patient With Acoustic Neuroma
In this case study, a clinical audiologist used Neuromod’s Lenire to treat a problem with tinnitus in a patient with acoustic neuroma.
All
Latest
Neuromod Announces Lenire Tinnitus Study Results
Neuromod Devices Ltd announced the findings of an independent study performed at the German Hearing Center (DHZ) at Hannover Medical School, which found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms (based on the Tinnitus Handicap Inventory score[i]Â across 20 patients) when using the Lenire treatment device.Â
Neuromod Appoints Susan Whichard to Board
Whichard has more than 30 years’ experience in the hearing industry, having worked as both a business executive and a practicing healthcare professional, as a clinical audiologist. Her appointment comes as Neuromod plans continued expansion of the availability of Lenire, its tinnitus treatment device across Europe and in the US, pending FDA approval, according to the company’s announcement.
Read More
Survey Shows Many Don’t Receive Tinnitus Treatment
New research from Irish medical device company, Neuromod Devices Ltd, has found that more than three quarters of people suffering from tinnitus in the United Kingdom have never received any treatment for their condition, according to an announcement on the company’s website. The poll also revealed that 67% of UK tinnitus sufferers don’t feel adequately informed about their condition.
Read More
Neuromod Raises $12.4 Million in Series B Funding for Lenire Tinnitus Treatment Device
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
Read More
Neuromod Publishes Results of Tinnitus Study Utilizing Non-invasive Stimulation Device
The clinical trial was conducted between 2016 and 2019 and was designed to track changes in tinnitus symptom severity. The trial investigated the bimodal neuromodulation approach, using Neuromod’s non-invasive stimulation device that delivers sound to the ears and electrical stimulation to the tongue.
Read More
Neuromod Appoints Rosemarie Tully as COO
In addition to her current responsibilities for corporate development and strategy, Ms Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms Tully will continue to report to Dr Ross O’Neill, Chief Executive Officer of Neuromod.
Read More
Neuromod Appoints Florian Elsaesser as Chief Commercial Officer
Elsaesser, a hearing aid industry expert, has worked in the sector for over 12 years in various executive positions for Sivantos and Siemens Audiology.
Read More
Neuromod Closes on $8.75 Million Funding Round
Proceeds from the financing will be used to accelerate ongoing European commercialization of the Company’s Lenire tinnitus treatment device; to scale-up manufacturing capacity to meet anticipated European demand, and to progress the Company’s US regulatory strategy to secure market entry into the United States, according to Neuromod’s announcement.
Read More
Neuromod Names New Members of Senior Leadership Team
Neuromod announces the appointment of Deborah Arthur as Head of Quality and Regulatory Affairs, Suzanne O’Rourke as Director of Quality and Regulatory Affairs, and Cathal Mc Fadden as Director of Operations.
Read More